李氏大藥廠(00950.HK):使用Pexa-Vec結合Socazolimab治療轉移性黑色素瘤第Ib/II期臨牀研究於中國入組首名患者
格隆匯11月16日丨李氏大藥廠(00950.HK)發佈公吿,於2021年10月21日,集團附屬公司中國腫瘤醫療有限公司(COF)就使用Pexa-Vec(表達粒細胞-巨噬細胞集落刺激因子╱滅活胸苷激酶的牛痘病毒)結合Socazolimab(抗PD-L1單克隆抗體,前稱ZKAB001)治療轉移性黑色素瘤的第Ib/II期臨牀研究於中國入組首名患者。
該研究由北京大學腫瘤醫院的郭軍教授牽頭,分為第Ib期及第II期兩期。一線治療無效造成局部擴散或轉移性黑色素瘤的患者使用結合療程的安全性及第II期建議劑量將在第Ib期評估,而此階段將入組最多12名患者。使用Socazolimab結合Pexa-Vec或Socazolimab單藥療法治療局部擴散或轉移性黑色素瘤患者的客觀緩解率及無進展生存期將於第II期評估。該期將入組合共45名患者。第Ib期研究的招募工作預期將於2022年六月完成。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.